Department of Nephrology, Osmania General Hospital, Hyderabad, India.
Department of Nephrology, Indraprastha Apollo Hospital, Delhi, India.
Nephrology (Carlton). 2021 Feb;26(2):142-152. doi: 10.1111/nep.13825. Epub 2020 Dec 28.
There is paucity of data on the epidemiology of end-stage kidney disease (ESKD) from South Asia and South-East Asia. The objective of this study was to assess the aetiology, practice patterns and disease burden and growth of ESKD in the region comparing the economies.
The national nephrology societies of the region; responded to the questionnaire; based on latest registries, acceptable community-based studies and society perceptions. The countries in the region were classified into Group 1 (High|higher-middle-income) and Group 2 (lower|lowermiddle income). Student t-test, Mann-Whitney U test and Fisher's exact test were used for comparison.
Fifteen countries provided the data. The average incidence of ESKD was estimated at 226.7 per million population (pmp), (Group 1 vs. Group 2, 305.8 vs. 167.8 pmp) and average prevalence at 940.8 pmp (Group 1 vs. Group 2, 1306 vs. 321 pmp). Group 1 countries had a higher incidence and prevalence of ESKD. Diabetes, hypertension and chronic glomerulonephritis were most common causes. The mean age in Group 2 was lower by a decade (Group 1 vs. Group 2-59.45 vs 47.7 years).
Haemodialysis was the most common kidney replacement therapy in both groups and conservative management of ESKD was the second commonest available treatment option within Group 2. The disease burden was expected to grow >20% in 50% of Group 1 countries and 78% of Group 2 countries along with the parallel growth in haemodialysis and peritoneal dialysis.
南亚和东南亚有关终末期肾病(ESKD)的流行病学数据稀缺。本研究旨在评估该地区的病因、实践模式以及ESKD 的疾病负担和增长情况,并比较各国的经济情况。
该地区的国家肾脏病学会根据最新的登记资料、可接受的社区研究和社会认知,对该问卷做出了回应。该地区的国家被分为 1 组(高/中高收入)和 2 组(低/中低收入)。使用学生 t 检验、Mann-Whitney U 检验和 Fisher 确切检验进行比较。
15 个国家提供了数据。ESKD 的平均发病率估计为 226.7/百万人(pmp)(1 组与 2 组相比,305.8 与 167.8 pmp),平均患病率为 940.8 pmp(1 组与 2 组相比,1306 与 321 pmp)。1 组国家的 ESKD 发病率和患病率较高。糖尿病、高血压和慢性肾小球肾炎是最常见的病因。2 组的平均年龄低了 10 岁(1 组与 2 组相比,59.45 与 47.7 岁)。
在两组中,血液透析都是最常见的肾脏替代治疗方法,而在 2 组中,ESKD 的保守治疗是第二常见的治疗选择。预计在 50%的 1 组国家和 78%的 2 组国家中,ESKD 的疾病负担将增长超过 20%,同时血液透析和腹膜透析也将平行增长。